Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vodafone Group Plc American Depositary Shares — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while Vodafone Group Plc American Depositary Shares trades at $15.85 (market cap $36.16B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 4.9× Spyre Therapeutics Inc. Common Stock's market cap, and Vodafone Group Plc American Depositary Shares pays a 3.46% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vodafone Group Plc American Depositary Shares for 5 Days on average.
| SYRE | VOD | |
|---|---|---|
Market Cap | $7.35B | $36.16B |
Volume | 1,624,631 | 6,634,765 |
Sector | Health | Media |
52-Week High | $108.92 | $17.68 |
52-Week Low | $22.18 | $11.20 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $6.35B | $81.31B |
Dividend Yield | — | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VOD trades at $15.555, up 1.07% today, amid a bearish technical signal. The company reported a net loss of $4.17B for 2025, though revenue grew to $37.45B. Positive cash flow from operations of $15.37B and a low EV/EBITDA of 4.33 suggest underlying value. Recent news highlights Vodafone's strategic focus on 5G rollout and cost synergies in the UK, targeting £1 billion by 2032.
The outlook is mixed; analyst consensus leans buy (48%) with potential from operational improvements, but risks include persistent net losses, high debt, and competitive pressures. The stock's current valuation metrics (P/S 0.82, P/B 0.64) indicate it may be undervalued if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vodafone Group Plc American Depositary Shares
Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.
Read more on VOD →
